TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06862219: A Multicenter, Phase 4, Open-label, Single-arm, Safety Study of Enfortumab Vedotin in Adult Indian Participants With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Sponsor: Astellas Pharma Global Development, Inc. · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,720,480

Rescue Site Savings

+$6,431,040

Unlock Full NCT06862219 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06862219 Rescue Dossier →